Estudo randomizado | A adição de trastuzumabe à quimioterapia neoadjuvante para câncer esofágico com superexpressão de HER-2 não melhorou os desfechos.

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário: Trastuzumab with chemoradiation and surgery does not improve outcomes for esophageal cancer patients – NRG Oncology

Comentário no Twitter

In a phase III trial in 203 pts with HER2+ oesophageal cancer, adding trastuzumab to neoadjuvant CRT did not significantly improve mDFS (19.6 vs 14.2 months; HR 0.99; P = 0.97). The incidence of grade 3 and 4 TRAEs was 43% & 21% vs 54% & 22%: https://t.co/wx0NmVMyCR #esocsm

— NatureRevClinOncol (@NatRevClinOncol) January 21, 2022